An interventional study of QI-GONG and control in PASC Post Acute Sequelae of COVID 19, sponsored by POCHIWU. Recruiting at 2 sites in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by POCHIWU · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · Taiwan.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 12th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →5 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18–100
National Taiwan University Hospital · Sites in Taiwan
Ages 6–18 · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages up to 18 · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 80 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 68 across the 11 interventional studies, 415 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with POCHIWU as lead sponsor.
POCHIWU has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05764538Chang Gung Memorial HospitalDAOIB for the Treatment of Brain Fog | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).
Study Objectives:
To assess whether Qi-Gong improves physiological function in individuals with PASC.
To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.
Study Design:
If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.
Participant Involvement:
Practice Qi-Gong three times per week for three months. Record physiological data monthly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Experimental Group :Qi-Gong(yijinjing)
Behavioral: QI-GONG and control
Control Group:routine care
QIGONG
Pulmonary Function Test (Forced vital capacity)
FVC,over 80% is better
Time frame: From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FEV1)
FEV1,over 80% is better
Time frame: From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FVCFEV1)
FVCFEV1,over 80% is better
Time frame: From enrollment to the end of treatment at 12 weeks
Heart rate variability
Low Frequency,40%-60%
Time frame: From enrollment to the end of treatment at 12 weeks
Heart rate variability
High Frequency,40%-60%
Time frame: From enrollment to the end of treatment at 12 weeks
Heart rate variability
LF/HF,0.6-2.5
Time frame: From enrollment to the end of treatment at 12 weeks
Heart rate variability
Heart rate variability ,25ms-70ms
Time frame: From enrollment to the end of treatment at 12 weeks
Quality of Life(The short version of the World Health Organization Quality of Life ,WHOQOL-BREF)
WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better
Time frame: From enrollment to the end of treatment at 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Apr 2025, 4 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →